Optiscan Imaging Limited · ASX:OIL

Optiscan Imaging — Australian Life Science Investment Summit 2012

20 slides from Optiscan Imaging's conference presentation, Nov 2, 2012

  1. Slide 1: Australian Life Science Investment Summit

    For personal use only Angus Holt – Executive Chairman Australian Life Science Investment Summit Melbourne, Australia 2 November 2012 1

  2. Slide 2: Disclaimer

    Disclaimer This presentation has been produced by Optiscan Imaging Limited (“Optiscan”) only and may contain forward-looking statements that are based on management’s current expectations, beliefs and assumptions and are subject to a number of risks and uncertainties. The forward-looking For persona

  3. Slide 3: Pioneers and leaders in live micro imaging technology

    For personal use only Pioneers and leaders in live micro imaging technology and systems allowing real time, in-vivo visualisation of tissue at a cellular level leading to improved, earlier, minimally invasive diagnosis and treatment 3

  4. Slide 4: Brief History of Optiscan - milestones

    Brief History of Optiscan - milestones  1994 For personal use only Optiscan founded by Peter Delaney and Martin Harris  1997 Optiscan raises $3m under its IPO and lists on the ASX  2001 FDA clearance and release of Stratum (skin scanner) World’s First human confocal endomicroscopy by OptiScan – “

  5. Slide 5: Brief History of Optiscan – funding sources

    Brief History of Optiscan – funding sources More than $95m invested over 15 years For personal use only Major Sources of Funding Milestones, $7 Royalties, $17 Equity, $40 Grants, $6 Sales, $21 5

  6. Slide 6: Mission

    Optiscan - Mission To provide benefits across the treatment For personal use only chain: • Patients • Physicians • Treatment facilities • Health systems, To deliver: • Earlier detection • More accurate diagnosis • More timely treatment • More efficient procedures 6

  7. Slide 7: Mission…a reality in GI

    Optiscan – Mission…a reality in GI For personal use only 2nd gen endomicroscope HD definition CCD camera scanner provides fast scanning reveals suspicious areas with and ultra-high definition “virtual stunning clarity biopsies”

  8. Slide 8: Markets /1

    Optiscan – Markets /1 Independently assessed annual addressable markets of >$1bn within For personal use only the $7bn (5% CAGR) medical endoscopy market Presently addressed or immediately addressable: • Flexible endomicroscopy • >20,000 procedures to date • >150 systems installed worldwide • 1st ge

  9. Slide 9: Markets /2

    Optiscan – Markets /2 • Rigid endomicroscopy For personal use only • Neurosurgery exclusively partnered with #1 player in the field, Carl Zeiss Meditec • 2 trials complete • Target FDA/CE 2013 • Price inelastic market • Research endomicroscopy • >50 systems installed worldwide • Oncology, neuroscien

  10. Slide 10: Future Markets

    Optiscan – Future Markets For personal use only • Multiple further near term GI applications • ENT • Opthalmology • Breast • Women’s health – endometriosis, cervical cancer • Prostate (robotic) • Liver • Pancreas • Lung & Pleura • Skin 10

  11. Slide 11: Team

    Optiscan – Team For personal use only 17 highly skilled and experienced staff with an aggregate 150+ years at Optiscan • Executive Chairman - Angus Holt, Bcom • Founder and Director of Technology and Clinical Affairs - Peter Delaney, BSc (Pharm)(Hons) • Finance Director – Bruce Andrew, B Bus, CPA •

  12. Slide 12: The Technology

    For personal use only The Technology

  13. Slide 13: Capabilities

    Optiscan - Capabilities For personal use only  Strong R&D team and pipeline  50 long life patents and growing  ISO 13485 accredited  State of the art manufacturing 13

  14. Slide 14: Trials and Validation /1

    Optiscan – Trials and Validation /1 For personal use only 14

  15. Slide 15: Trials and Validation /2

    Optiscan – Trials and Validation /2  Gastroenterology Trials: Over 100 published studies containing For personal use only original clinical trial data  Trials in U.S., Germany, France, Italy, China, Singapore, Australia  Multi-center European trials led by Johannes Gutenberg University  Multi-ce

  16. Slide 16: Competition Analysis – Optiscan v Mauna Kea Technologies /1

    Competition Analysis – Optiscan v Mauna Kea Technologies /1 Parameter Optiscan Position For personal use only Form COMPARABLE Workflow SUPERIOR Lateral Resolution SUPERIOR+++ (smallest object can be seen distinctly) Axial Resolution SUPERIOR+++ (thinnest visible layer of cells) Field of View SUPERIO

  17. Slide 17: Competition Analysis – Optiscan v Mauna Kea Technologies /2

    Competition Analysis – Optiscan v Mauna Kea Technologies /2 Parameter Optiscan Position For personal use only Frame Speed COMPARABLE Probe Sizes OPTISCAN LARGER Robustness of Probes SUPERIOR+++ System Pricing COMPARABLE Level 1 Clinical Evidence OPTISCAN ONLY Independent Technology Comparison Studie

  18. Slide 18: Business Model

    Optiscan – Business Model For personal use only  Develop world leading microscopy systems for live micro imaging (continuing R&D)  Partner with relevant market leaders and leverage their existing and proven marketing and distribution channels  Sources of revenue (GM >50%)  System sales  Service

  19. Slide 19: OPTISCAN – at an inflection point

    OPTISCAN – at an inflection point For personal use only Strong IP (50 patents) and R&D pipeline  Quality accredited – ISO 13485  Significant partner (Zeiss, Pentax) and trial validation  Independent competitor comparison trials show  Optiscan superior Proven regulatory clearance history since 20

  20. Slide 20: optiscan.com

    For personal use only optiscan.com 20

Optiscan Imaging — Australian Life Science Investment Summit 2012 on 6ix